Albireo Pharma Inc Marktkapitalisierung
Was ist das Marktkapitalisierung von Albireo Pharma Inc?
Marktkapitalisierung von Albireo Pharma Inc ist $492.28M
Was ist die Definition von Marktkapitalisierung?
Die Marktkapitalisierung ist der Marktwert zu einem Zeitpunkt, zu dem die Aktien eines börsennotierten Unternehmens im Umlauf sind, und ist gleich dem Aktienkurs zu diesem Zeitpunkt multipliziert mit der Anzahl der im Umlauf befindlichen Aktien .
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Marktkapitalisierung von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Albireo Pharma Inc
Was macht Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Unternehmen mit marktkapitalisierung ähnlich Albireo Pharma Inc
- NOCIL hat Marktkapitalisierung von $491.44M
- Nektar Therapeutics hat Marktkapitalisierung von $491.50M
- Tejon Ranch Co hat Marktkapitalisierung von $491.61M
- Sisram Medical Ltd hat Marktkapitalisierung von $491.70M
- enCore hat Marktkapitalisierung von $491.81M
- Garrett Motion Inc hat Marktkapitalisierung von $491.97M
- Albireo Pharma Inc hat Marktkapitalisierung von $492.28M
- Brasilagro Companhia Brasileira De Propriedade Agricola hat Marktkapitalisierung von $492.33M
- Premier Gold Mines hat Marktkapitalisierung von $493.21M
- Beijing Enterprises Clean hat Marktkapitalisierung von $493.64M
- Xinyuan Ppty Mgmt Svc hat Marktkapitalisierung von $493.73M
- IQE Plc hat Marktkapitalisierung von $494.04M
- South Plains Inc hat Marktkapitalisierung von $494.72M